Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
City Of Hope National Medical Center · University of California, Los Angeles · +13 more institutions
Abstract
Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy.
This double-blind study compared the effect of palifermin with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous hematopoietic stem-cell transplantation. Oral mucositis was evaluated daily for 28 days after transplantation.
Citation impact
- FWCI
- 55.88
- Percentile
- 100%
- References
- 31
Authors
17- RSRicardo SpielbergerCorresponding
City Of Hope National Medical Center, University of California, Los Angeles, City of Hope
- PJPatrick J. Stiff
University of California, Los Angeles, Loyola University Medical Center
- WBWilliam Bensinger
Fred Hutch Cancer Center, Cancer Research Center, University of California, Los Angeles
- TGTeresa Gentile
University of California, Los Angeles, SUNY Upstate Medical University, Syracuse University
- DJDaniel J. Weisdorf
University of California, Los Angeles, University of Minnesota
Topics & keywords
- Mucositis
- Medicine
- Radiation therapy
- Complication
- Chemotherapy
- Stomatitis
- Dermatology
- Internal medicine
- Good health and well-being